Vincenzo Colangeli

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients

Antonella d’Arminio Monforte, Alessandro Cozzi‐Lepri, Giovanni Rezza et al. · AIDS · 2000 · 556 citations

Human Herpesvirus 8 Seropositivity and Risk of Kaposi's Sarcoma and Other Acquired Immunodeficiency Syndrome-Related Diseases

Giovanni Rezza, Massimo Andreoni, Maria Dorrucci et al. · JNCI Journal of the National Cancer Institute · 1999 · 132 citations

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia

Leonardo Calza, Roberto Manfredi, Vincenzo Colangeli et al. · AIDS · 2005 · 103 citations

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients

Maria Carla Re, M. Vignoli, G. Furlini et al. · Journal of Clinical Virology · 2001 · 94 citations

Primary Immunodeficiency, Human Retrovirus, Hiv-1 Seropositive Patients +10

Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

Leonardo Calza, Vincenzo Colangeli, Roberto Manfredi et al. · AIDS · 2005 · 77 citations

Protease Inhibitors, Thrombosis, Lipid Disorder +15